Superfluid Dx
Signal active
Organization
Contact Information
Overview
Tissue-specific cell-free circulating RNA is a newly developed area for molecular diagnosis. Based on this powerful non-invasive approach, Molecular Stethoscope aims to transform healthcare by providing early insight into a patient’s healthy versus disease state.
About
Industries
Biotechnology, Life Science, Health Care, Pharmaceutical
Founded
2015
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Superfluid Dx headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $393.6M in funding across 48 round(s). With a team of 11-50 employees, Superfluid Dx is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Superfluid Dx, raised $8.2M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
4
Lead Investors
0
Total Funding Amount
$8.2M
Details
2
Superfluid Dx has raised a total of $8.2M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2023 | Early Stage Venture | |||
| 2017 | Seed | 8.2M |
Investors
Superfluid Dx is funded by 13 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Pfizer | - | FUNDING ROUND - Pfizer | 8.2M |
| Index Ventures | - | FUNDING ROUND - Index Ventures | 8.2M |
| Superfluid Dx | - | FUNDING ROUND - Superfluid Dx | 8.2M |
| AAF Management Ltd. | - | FUNDING ROUND - AAF Management Ltd. | 8.2M |
Recent Activity
There is no recent news or activity for this profile.